Light Sciences Oncology Inc., a Snoqualmie, Wash.-based developer of light-activated treatments for solid tumors, has raised $35 million in debt and option financing, according to a regulatory filing. VentureWire refers to the round as “bridge financing” as it considers a second stab at the IPO market. LSO had filed for an IPO in early 2006, but pulled it in 2008 citing ”unfavorable market conditions.”
At the time, LSO had raised nearly $99 million in VC funding since 2005, from firms like Essex Woodlands Health Ventures, Scandinavian Life Science Venture, Novo AS, New Science Ventures, China Industrial Development Bank and Johnson & Johnson Development Corp. www.lsoncology.com